[Controlled release of paclitaxel from microparticles containing PLLA and its anti-tumor activity on human ovarian carcinoma cell line].
OBJECTIVE
To prove the PLLA-PTX' efficacy on growth, apoptosis of ovarian cancer cell line SKOV3, and to study the controlled release roles of PLLA for PTX.


METHODS
Cultured cells of human ovarian Carcinoma cell Line SKOV3 were treated with PLLA-PTX microparticles and PTX only separately, untreated cells as the control. The proliferation of SKOV3 cells were determined by MTT assay with the morphologic change observed under inverted phase contrast microscope, the apoptosis of cell were demonstrated by FCM and in situ TUNEL technique.


RESULTS
The anti-tumor activity of PLLA-PTX microparticles was stronger than PTX alone. A time-dependent and dose-dependent growth inhibition was abserved. At 0.05 micromol/L drug concentration, SKOV3 cell viability experiment demonstrated that the drug formulated in the microparticles was more effective than that formulated in PTX. PLLA-PTX microparticles can increase G2/M period percentage, interrupt the cell cycle proceeding, and inhibit the tumor cells'growth through cell apoptosis. Positive staining for the presence of apoptosis were obtained in SKOV3 cells with PLLA-PTX microparticles.


CONCLUSIONS
PLLA-PTX microparticles have strong anti-tumor activity and obviously controlled released effectiveness. It shows longer and stronger controlled anti-tumor activity than paclitaxel alone.
Yang
Qin
Q
Department of Obstetrics and Gynecology, West China Second Hospital, Sichuan University Chengdu 610041, China.
Kang
Yun-qing
YQ
Wang
Hong-jing
HJ
Yin
Guang-fu
GF
Fang
Kun
K
Yang
Kun
K
D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D019344:Lactic Acid / Q000494:pharmacology*; D010051:Ovarian Neoplasms / Q000473:pathology*; D017239:Paclitaxel / Q000494:pharmacology*; D010316:Particle Size; D011091:Polyesters; D011108:Polymers / Q000494:pharmacology*
D000972:Antineoplastic Agents, Phytogenic; D003692:Delayed-Action Preparations; D011091:Polyesters; D011108:Polymers; D019344:Lactic Acid; C033616:poly(lactide); D017239:Paclitaxel